Opinion

Patent owners need to get wise to a possible changing of the guard at the Federal Circuit

Judge Wallach’s decision to take senior status might be the first of several and with billions in recent damages verdicts heading the court’s way, any new appointments could prove particularly consequential

27 March 2021

China’s IP world is set for a big shift to auto

Huawei, ZTE and other leading domestic high-tech players are moving in and they will help shape the landscape for transactions, litigation and licensing

20 March 2021

Patent licensing does not deserve the unfair rap it gets

Everyone in the IP eco-system should promote the benefits of an activity that has delivered so much to so many in all parts of the world – but recognise its flaws, too

13 March 2021

Creative monetisation of de-prioritised IP is the next frontier for Big Pharma strategists

Despite their commitments to specialisation, large life sciences companies must not neglect the value of sidelined patents, know-how and other intangible assets

06 March 2021

India is staring at some of the biggest opportunities in global IP

Decision to abolish troubled patent board is the right one, but policymakers should double down on reform

27 February 2021

Why the US must now take the lead on SEP FRAND

Being a rule taker does not sit well with American interests nor with those of the wider global patent community. It is time for a change of approach

20 February 2021

The cleantech gap in Big Oil patent portfolios spells more M&A in the sector

The supermajors are not creating big IP stockpiles in green energy, which means there could be opportunities for others

13 February 2021

No, IP rights are not the barrier to covid-19 vaccine supplies

Continued criticism of biopharma patent owners fails to acknowledge that manufacturing and supply complexities are the real obstacles to mass inoculation around the world

06 February 2021

Love him or loathe him, few USPTO directors have left an impression like Iancu

From new 101 guidelines to PTAB reform and changing the narrative around innovation, America’s now former IP chief built a considerable legacy

29 January 2021

Rebooting IP engagement with China need not mean giving up ground on key concerns

The patent world functions better when its two most powerful players have a constructive, though competitive, relationship

23 January 2021

China needs more patent attorneys, but lowering standards is not the answer

Recent measures that widen the door to the sector raise concerns over quality

16 January 2021

Revealed: the email Andrei Iancu sent to USPTO staff on the day the US Capitol was stormed

“I am heartbroken to see this affront to our constitutional electoral process,” the agency’s Director wrote

09 January 2021

It’s time for investors to re-assess intangibles

A recent report suggests Wall Street is beginning to realise that the rise of intangible assets has thrown a spanner into time-tested valuation models

12 December 2020

Another Yahoo! or the new Nortel? The challenges of valuing BlackBerry's patents

As interested parties start to make their plays, there's still plenty of uncertainty around how much the Canadian tech giant's portfolio of assets might go for

04 December 2020

The EU has the chance to seize global patent leadership

Europe has never been in a better position to set rules the rest of the world must follow

28 November 2020

RCEP is a leap for China but a small step for IP

World’s largest trade pact is not a show-stopper when it comes to IP, but it will bring changes to ASEAN and clouds US ability to set regional agenda

21 November 2020

The dangers of the EPO move to opposition hearings by video conference

A recent announcement by the agency will increase transparency but could have several unintended – and potentially troublesome – consequences

14 November 2020

A Biden presidency is likely to mean IP evolution, not revolution

With the former vice-president closing in on election victory, we take a look at how his administration might tackle key patent issues

07 November 2020

Despite apparent convergence, life sciences and high-tech IP management will remain worlds apart

Pharma and biotech companies can learn from how strategies are developed in other sectors, but will still have to forge their own paths to meet new challenges

31 October 2020

To educate lawyers who change the world, we cannot let this crisis go to waste

As the covid-19 pandemic continues to upend education in the US and beyond, there is an opportunity to create a new normal in how IP is taught, says Megan Carpenter, Dean of the Franklin Pierce School of Law

24 October 2020

Get unlimited access to all IAM content